Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer
Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer: A Prospective Cohort Study
The objective of this observational study is to evaluate the oncological safety of breast-conserving surgery combined with standard postoperative radiotherapy in adult female patients diagnosed with multifocal or multicentric breast cancer. The main questions it aims to answer are:
What is the local recurrence rate and the time distribution of local recurrence after breast-conserving therapy in patients with multifocal or multicentric breast cancer? What independent risk factors are associated with postoperative local recurrence among these patients? There is no separate comparison group in this single-arm prospective cohort study.
Participants will:
Receive standardized breast-conserving surgery plus routine postoperative radiotherapy and individualized adjuvant therapy in accordance with clinical guidelines; Complete regular clinical follow-up visits, telephone and WeChat follow-ups for at least 3 years after surgery to collect data on surgical complications, tumor recurrence, metastasis and survival status; Fill out standardized questionnaires including Breast-Q, SDS, SAS and EORTC QLQ-C30 to assess postoperative breast satisfaction, psychological status and quality of life.
研究概览
地位
条件
详细说明
This single-center, single-arm prospective observational cohort study enrolls female patients aged ≥18 years with unilateral multifocal or multicentric breast cancer treated at the Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University. Subjects are screened in strict accordance with unified inclusion and exclusion criteria. All enrolled patients receive breast-conserving surgery followed by standardized postoperative radiotherapy and individualized adjuvant therapy without trial-specific interventions, and all treatment regimens are formulated in line with domestic guidelines for breast cancer diagnosis and treatment. All participants sign written informed consent prior to enrollment.
Uniform baseline data including demographic characteristics, menstrual and reproductive history, family history of malignancy, imaging findings, pathological profiles, molecular subtypes, and surgical information are collected. Postoperative 30-day surgical complications are documented to evaluate short-term surgical safety. Standardized long-term follow-up lasting no less than 3 years is conducted after surgery via outpatient visits, telephone calls and WeChat communication to continuously track oncological endpoints such as ipsilateral breast tumor local recurrence, regional lymph node recurrence, contralateral breast malignancy and distant metastasis, as well as data on disease-free survival and overall survival. Validated standardized questionnaires including Breast-Q, SDS, SAS and EORTC QLQ-C30 are administered at scheduled follow-up time points to assess patients' satisfaction with breast appearance, anxiety and depression status, and overall quality of life.
All data are double-entered, subjected to regular quality control and anonymized for privacy protection. Statistical analyses consist of descriptive statistics, univariate analyses, multivariate Logistic regression, Cox proportional hazards regression, and Kaplan-Meier survival analysis. Subgroup analyses stratified by molecular subtype, lesion distribution pattern and axillary lymph node status are performed, and a nomogram predicting the risk of postoperative local recurrence is constructed to facilitate individualized clinical risk assessment.
Patients with inflammatory breast cancer, extensive lesions precluding negative surgical margins, severe vital organ dysfunction, pregnancy or lactation incompatible with radiotherapy, or inability to complete long-term follow-up are excluded from the study. Lost-to-follow-up cases are treated as censored data in survival analyses, and baseline characteristics are compared between lost and fully followed patients to mitigate attrition bias. This study receives no external funding. All study procedures strictly comply with the Declaration of Helsinki and institutional ethical review requirements. The study aims to clarify the oncological safety of comprehensive breast-conserving therapy for multifocal or multicentric breast cancer, identify independent risk factors for postoperative local recurrence, and provide native evidence-based references for individualized surgical management of such patients in China.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:WenBin Zhou, Ph.D
- 电话号码:025-68308161
- 邮箱:Zhouwenbin@njmu.edu.cn
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Female patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Pathologically confirmed invasive breast carcinoma or ductal carcinoma in situ (DCIS);
- Radiologically confirmed unilateral multifocal or multicentric breast cancer;
- No systemic distant metastasis detected on preoperative imaging;
- Comprehensive clinical evaluation predicts all tumor lesions can be completely resected by breast-conserving surgery (BCS) to obtain negative surgical margins, and patients are suitable for standardized adjuvant whole-breast radiotherapy postoperatively;
- Adequate function of vital organs (cardiac, hepatic, renal and hematopoietic systems) to tolerate surgery, subsequent adjuvant radiotherapy and chemotherapy;
- Voluntarily agree to participate in the study after fully understanding the study purpose, procedures, potential risks and benefits, and provide written informed consent.
Exclusion Criteria:
- Inflammatory breast cancer;
- Extensive tumor burden that prevents complete resection via breast-conserving surgery or attainment of negative surgical margins;
- Severe dysfunction or failure of vital organs (heart, liver, kidney, lung) making patients unable to tolerate surgery, radiotherapy or chemotherapy;
- Pregnant or lactating women who are ineligible for postoperative radiotherapy;
- Patients who are unwilling or unable to complete long-term postoperative follow-up and data collection.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Multifocal or Multicentric Breast Cancer Patients Undergoing Breast-Conserving Surgery
This cohort consists of female patients aged ≥18 years with pathologically confirmed unilateral multifocal or multicentric breast cancer who meet all inclusion and exclusion criteria.
All participants receive standardized breast-conserving surgery combined with sentinel lymph node biopsy or axillary lymph node dissection as clinically indicated.
Postoperatively, all subjects undergo standard adjuvant radiotherapy followed by individualized systemic adjuvant therapy (chemotherapy, endocrine therapy, anti-HER2 targeted therapy) formulated in accordance with national breast cancer clinical guidelines.
No investigational interventions are administered, all treatments are routine standard clinical care.
Participants will complete long-term follow-up for at least 3 years and finish validated patient-reported outcome (PRO) questionnaires at scheduled visits.
|
All patients receive routine standard clinical treatment rather than investigational interventions, including breast-conserving surgery, axillary staging surgery, postoperative adjuvant radiotherapy, and guideline-concordant chemotherapy, endocrine therapy or anti-HER2 targeted therapy according to pathological and molecular characteristics.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Local recurrence rate of ipsilateral breast
大体时间:3 years after surgery
|
Ipsilateral breast local recurrence rate within 3 years after breast-conserving surgery
|
3 years after surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of postoperative surgical complications
大体时间:Within 3 years after surgery
|
Incidence of short-term complications after surgery, short-term complications (hemorrhage, wound infection, skin flap necrosis) occurring within 30 days after surgery.
Long-term upper extremity lymphedema will be monitored for up to 3 years.
|
Within 3 years after surgery
|
|
Disease-free survival (DFS)
大体时间:3 years after surgery
|
DFS is defined as the time interval from surgery to the first event of tumor recurrence, distant metastasis, or breast cancer-related death.
|
3 years after surgery
|
|
Overall survival (OS)
大体时间:At least 3 years after surgery
|
OS is defined as the time from surgery to all-cause death
|
At least 3 years after surgery
|
|
Regional lymph node recurrence rate
大体时间:3 years after surgery
|
Incidence of ipsilateral axillary regional lymph node recurrence during follow-up
|
3 years after surgery
|
|
Contralateral breast malignancy rate
大体时间:3 years after surgery
|
Incidence of new malignant lesions in the contralateral breast
|
3 years after surgery
|
|
Distant metastasis rate
大体时间:3 years after surgery
|
Incidence of systemic distant metastasis at any site during follow-up
|
3 years after surgery
|
|
Breast-Q patient-reported outcome
大体时间:Baseline, 1 year, 2 years and 3 years after surgery
|
Patient-reported breast satisfaction and cosmetic outcomes assessed via the validated Breast-Q questionnaire.
|
Baseline, 1 year, 2 years and 3 years after surgery
|
|
Self-rating anxiety scale (SAS) score
大体时间:Baseline, 1 year, 2 years and 3 years after surgery
|
Anxiety status measured by the validated Self-Rating Anxiety Scale (SAS).
|
Baseline, 1 year, 2 years and 3 years after surgery
|
|
Self-rating depression scale (SDS) score
大体时间:Baseline, 1 year, 2 years and 3 years after surgery
|
Depressive symptoms assessed using the validated Self-Rating Depression Scale (SDS).
|
Baseline, 1 year, 2 years and 3 years after surgery
|
|
EORTC QLQ-C30 global quality of life score
大体时间:Baseline, 1 year, 2 years and 3 years after surgery
|
Overall cancer-related quality of life evaluated with the validated EORTC QLQ-C30 questionnaire.
|
Baseline, 1 year, 2 years and 3 years after surgery
|
合作者和调查者
出版物和有用的链接
一般刊物
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
- Poenaru MO, Amza M, Toma CV, Augustin FE, Pacu I, Zampieri G, Ples L, Sima RM, Diaconescu AS. Multicentric and Multifocal Breast Tumors-Narrative Literature Review. Cancers (Basel). 2025 Oct 20;17(20):3380. doi: 10.3390/cancers17203380.
- Sun Y, Gao L, Zhou X, Wang Z, Li Y, Sun Q. Local Recurrence and Survival Outcomes of Multifocal/Multicentric Breast Cancer After Breast Conserving Therapy: A systematic Review and Meta-Analysis. Clin Breast Cancer. 2025 Apr;25(3):e229-e239.e9. doi: 10.1016/j.clbc.2024.10.009. Epub 2024 Oct 18.
- Masannat YA, Rocco N, Garreffa E, Gulluoglu BM, Kothari A, Maglia A, Nava MB, Omar OS, Potter S, Catanuto G. Global variations in the definition and management of multifocal and multicentric breast cancer: the MINIM international survey. Br J Surg. 2022 Jul 15;109(8):656-659. doi: 10.1093/bjs/znac080. No abstract available.
- De Lorenzi F, Borelli F, Pagan E, Bagnardi V, Peradze N, Jereczek-Fossa BA, Leonardi C, Mazzarol G, Favia G, Corso G, Montagna E, Rietjens M, Veronesi P. Oncoplastic Breast-Conserving Surgery for Synchronous Multicentric and Multifocal Tumors: Is It Oncologically Safe? A Retrospective Matched-Cohort Analysis. Ann Surg Oncol. 2022 Jan;29(1):427-436. doi: 10.1245/s10434-021-10800-w. Epub 2021 Oct 6.
- Koppiker C, Joshi S, Mishra R, Kelkar DA, Chigurupati P, Joshi A, John J, Kadu S, Bagdia A, Thakkar D, Deshmukh C, Allampati H, Sharan G, Dhar U, Nare S, Nagarkar S, Busheri L, Varghese B, Pai M. Therapeutic mammoplasty: a "wise" oncoplastic choice-lessons from the largest single-center cohort from Asia. Front Oncol. 2023 Apr 14;13:1131951. doi: 10.3389/fonc.2023.1131951. eCollection 2023.
- Zhang J, Fang H, Zhao Z, Guo Y, Li Y, Wang Y, Guo X, Ning Z, Wang H. Clinicopathological characteristics and prognostic analysis of multifocal/multicentric breast cancer. Sci Rep. 2025 Dec 29;15(1):44869. doi: 10.1038/s41598-025-28687-y.
- Tong Y, Sun F, Zhang C, Yang S, Yu Z, Zhao Y. Multifocal/multicentric breast cancer: Does each focus matter? Cancer Med. 2023 Apr;12(7):8815-8824. doi: 10.1002/cam4.5626. Epub 2023 Feb 3.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- NJMU-BC14
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.